Insilico Medicine (HKG:3696) has nominated a new preclinical drug candidate for glioblastoma using its artificial intelligence platform, according to a Friday Hong Kong bourse filing.
The candidate, ISM0387, was developed by the company's United Arab Emirates team using its Pharma.AI system and progressed from design to optimization in under 12 months.
Insilico said the drug showed improved activity, selectivity, and brain penetration in early studies, with potential as a treatment for brain cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments